TELA
TELA Bio Inc

315
Mkt Cap
$32.77M
Volume
1,542.00
52W High
$2.48
52W Low
$0.6671
PE Ratio
-0.83
TELA Fundamentals
Price
$0.7794
Prev Close
$0.7358
Open
$0.7142
50D MA
$0.9006
Beta
0.79
Avg. Volume
359,116.39
EPS (Annual)
-$1.33
P/B
19.06
Rev/Employee
$331,578.95
$76.54
Loading...
Loading...
News
all
press releases
Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of +252.25% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
More News
News Placeholder
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly
TELA Bio is suing Becton Dickinson for allegedly abusing its monopoly power in the hernia mesh market to limit competition and harm patients.read more...
Benzinga·3mo ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -200.00% and +1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +33.33% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
<
1
2
...
>

Latest TELA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.